As far as we know, the precise mechanism by which PCSK7 decreases HDL-C and/or increases triglyceride levels in adverse events such as ACS, hypertriglyceridemia, and liver disease remains to be elucidated. This evidence concerns the gene PCSK7 and liver disorder.